Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: Study of sixteen patients;Etude de seize cas d'hépatite C aiguë: Essai de traitement précoce par l'interféron alpha- 2b ou interféron alpha- 2b et ribavirine

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 I, 2003, Pages 294-299

  Rocca, Pierre ^a   Bailly, François ^a   Chevallier, Michèle ^b   Chevallier, Philippe ^c   Zoulim, Fabien ^a   Trépo, Christian ^a  

^a HÔTEL DIEU   (France)

^b LMM Laboratoire Marcel Merieux   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ACUTE HEPATITIS; ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL STUDY; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; MEDICAL ASSESSMENT; NEEDLESTICK INJURY; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME; VIROLOGY; VIRUS TRANSMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; ASTHENIA; DIARRHEA; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; JAUNDICE; MALE; MIDDLE AGED; NEEDLESTICK INJURIES; PAIN; PUNCTURES; RETROSPECTIVE STUDIES; RIBAVIRIN; SEROTYPING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TATTOOING; TIME FACTORS; TREATMENT OUTCOME;

EID: 0344716597     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Who. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72: 341-4.
2. Desenclos JC. Epidémiologie de l'hépatite C. Rev Prat 2000;50:1066-70.
3. Dubois F, Desenclos JC, Mariotte N, Goudeau A, and the collaborative study group. Hepatitis C in a french population-based survey, 1994; seroprevalence, frequency of viremia, genotype distribution, and risk factors? Hepatology 1997;25:1490-6.
4. Desenclos JC, Dubois F, Couturier E, Pillonel J, Roudot-Thoroval F, Guignard E, et al. Estimation du nombre des sujets infectés par le VHC en France, 1994-1995. Bull Epidemiol Hebdo 1996;5:22-3.
5. Hézode C, Dhumeaux D. Traitement de l'hépatite chronique virale C: présent et futur. Gastroenterol Clin Biol 2000;24:533-5.
6. Neumann AU, Lam NP, Dahari H, Grecht DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-therapy. Science 1998;282:103-7.
7. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-71.
8. Manns MP, Mchutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Ling M, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
9. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.
10. Farci P, Alter HJ, Wong D, Ritter RH, Shih JW, Jett B, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
11. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C. Hepatology 1995;21:639-44.
12. Balart LA, Perillo P, Roddenberry J, Regenstein F, Shim KS, Shieh YS, et al. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 1993;104:1472-7.
13. Alberti A, Morsica G, Chemello L, Carvalletto D, Noventa F, Pontisso P, et al. Hepatitis C viraemia and liver disease with anti-HCV. Lancet 1992;340:697-8.
14. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, et al. Long-term follow-up non-A non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
15. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-41.
16. Muir AJ, Rockey DC. Acute HCV: the early bird catches the virus. Gastroenterology 2002;122:1176-81.
17. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-44.
18. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective of long-terme outcome. Semin Liver Dis 2000;20:17-35.
19. Farci P. Hepatitis C virus. The importance of viral heterogeneity. Clin Liver Dis 2001;5:895-916.
20. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of C virus putative enveloppe glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci Usa 1992;89:3468-72.
21. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995;208:653-61.
22. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alpha-2b. N Engl J Med 2001;345:1452-7.
23. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effect of dose and duration. Hepatology 1996;24:778-89.
24. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996;41:1248-55.
25. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999;31(suppl 1):189-92.
26. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-alpha 2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996;41:81s-85s.
27. Quin JW. Interferon therapy for acute hepatitis C viral infection: a review by meta-analysis. Aust Nzj Med 1997;27:611-8.
28. Couzigou P. Quelles sont les précautions à prendre en cas d'hépatite C? Conférence de consensus - texte des experts. Gastroenterol Clin Biol 1997;20:s11-s120.
29. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle RH, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro-neutralization. Proc Natl Acad Sci USA 1994;91:7792-6.
30. Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C infection. Hepatology 1992;16:877-81.
31. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C virus in asymptomatic blood donors. Hepatology 1997;26(suppl 1):295-335.
32. Theodore D, Fried MW. Natural history and disease manifestations of hepatitis C infection. Curr top Microbiol Immunol 2000;242:43-54.
33. Schioda A, Moriyama M, Hayashi N. Immunoglobulin G and M hepatitis C virus core antibody (jcc.2) response in chimpanzees infected experimentally with hepatitis C virus. Intervirology 2000;43: 146-53.
34. Morand P, Dutertre N, Minazzi H, Burnichon J, Pernollet M, Baud M, et al. Lack of seroconversion in a health-care worker after polymerase chain reaction-documented acute hepatitis C resulting from a needlestick injury. Clin Infect Dis 2001;33:727-9.